Skip to main content

Table 3 Risk for development of RA in individuals before the onset of any symptoms of disease (n = 370)

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

Antibodies

Frequency

OR (95% CI)

OR (95% CI)

OR (95% CI)

 

N (%)

 

Adjusted for smoking

Adjusted for HLA-SE

   

(n = 348)

(n = 366)

Anti-CCP2

129 (34.9)

21.83 (12.33–38.67)

21.69 (11.96–39.33)

19.52 (10.96–34.79)

Anti-CEP-1/Eno5-21

107 (28.9)

6.27 (4.16–9.43)

5.69 (3.74–8.66)

5.57 (3.67–8.46)

Anti-CitC1359-369

47 (13.1)

3.32 (2.00–5.50)

3.04 (1.82–5.10)

3.27 (1.94–5.50)

Anti-Fibα580-600 (591)

31 (8.7)

1.46 (0.88–2.41)

1.39 (0.82–2.36)

1.54 (0.91–2.61)

Anti-Fibα563-583 (573)

40 (10.8)

2.20 (1.34–3.60)

2.10 (1.25–3.53)

2.15 (1.29–3.57)

Anti-Fibβ62-81a (72)

43 (11.6)

4.06 (2.30–7.16)

4.42 (2.47–7.91)

3.44 (1.92–6.17)

Anti-Fibβ62-81b (74)

57 (15.9)

10.68 (5.38–21.22)

10.05 (5.02–20.10)

9.48 (4.72–19.05)

Anti-Fibβ36-52

110 (29.7)

5.97 (4.01–8.88)

6.07 (4.00–9.22)

5.66 (3.76–8.51)

Anti-CCP-1/Fil307-324

97 (26.2)

11.64 (6.82–19.88)

12.10 (6.94–21.10)

10.39 (6.03–17.90)

Anti-Vim60-75

48 (13.0)

2.61 (1.63–4.19)

2.37 (1.45–3.88)

2.50 (1.54–4.08)

Anti-Vim2-17

29 (7.0)

1.90 (1.06–3.40)

1.55 (0.85–2.85)

1.85 (1.01–.3.39)

  1. OR= odds ratio, CI= confidence intervals, anti-CCP2=anti-cyclic citrullinated peptide antibodies, anti CEP-1/Eno5-21= antibodies against α-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.